Last reviewed · How we verify
NCT06270017: ZEBRA-COLON
Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars
Phase 1, PHASE2 trial testing Chemotherapy drug in Colon Cancer in 300 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | University Hospital, Linkoeping |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 300 |
| Start date | 10 January 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Chemotherapy drug — full drug profile →
Conditions studied
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
University Hospital, Linkoeping
Who can join
18 and older, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to improve and individualize cancer treatment personalized treatments developed much further. Colon cancer is treated with surgery and thereafter adjuvant oncological treatment. The selection of chemotherapy is today mainly done according to best guess. Today only a small fraction of oncological treatment may be known to be effective in a person before treatment start, most often it is trial and error. A fast reliable system for looking at response to different treatments in each unique patient is much needed and would, if successful, completely change the way we give oncological treatment today. This system would also be possible to use to evaluate new treatments and if successful, implement in the clinical setting. In this project we will implant a part of the patient's tumour tissue into a zebrafish embryo and evaluate tumour growth and frequency of metastatic disease as well as response to given oncological treatment. 2.2 Objective: The objective of this project is to explore the usefulness of zebrafish (Danio Rerio) embryo models to determine tumor biology and treatment response in colon cancer. An overarching goal would be, before start of any oncological treatment in a patient, to have evaluated the response of oncological treatment in the zebrafish avatar and only treat with a combination of drugs known to have effect against the patient's own tumour. 2.3 Study design: This protocol describes a series of prospective studies in different cohorts of patients with colon cancer to investigate the applicability of zebrafish embryo models. The common denominator of the sub-studies is prospective collection of tumor tissue implanted in zebrafish embryos in order to evaluate if the model is robust enough for growing colon cancer tissue and evaluate growth pattern and response to chemotherapy. This study protocol is designed according to and in adherence with the SPIRIT guidelines. 2.4 Intervention: In all sub-studies the intervention is inoculation of tumor cells in zebrafish embryos followed by observation of tumor behavior and testing of treatments.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Zebrafish as a Model for Translational Immuno-Oncology.
Barbosa GR, de Souza AM, Silva PF, Fávero CS, et al · · 2025 · cited 1× · PMID 40710421 · DOI 10.3390/jpm15070304
Verify or expand the search:
- PubMed search for NCT06270017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy drug
Trials testing the same drug.
- NCT05798845 — The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT06841952 — Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute My · NA · not yet recruiting
- NCT06446388 — Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
- NCT06840119 — Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers · Phase 1, PHASE2 · recruiting
- NCT07096180 — Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer · recruiting
Other recruiting trials for Colon Cancer
Currently open trials in the same condition.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
- NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
- NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
- NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
Other University Hospital, Linkoeping trials
Trials by the same sponsor.
- NCT07275086 — Therapeutic Outcomes of Using Complementary Hand-based Treatment in Diabetes · NA · not yet recruiting
- NCT07499024 — Evaluation of the Diagnostic Performance of the Testicular Workup for Ischemia and Suspected Torsion (TWIST) Score for A · recruiting
- NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
- NCT07211295 — Accurate AI-based Characterisation of Surface Size, Depth and Tissue Composition in Hard-to-Heal Wounds · completed
- NCT06869148 — Evaluation of Prioritized Assessment for Older Patients Living With Frailty Presenting to the Emergency Department · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06270017 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Linkoeping
- Last refreshed: 21 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06270017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing